Mukul Verma 1/4/23 Mukul Verma 1/4/23 Cancer Focus Fund Invests $5 Million to Support Human Trial of ISA's Immunotherapy to treat Uveal Melanoma Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in Rare Ocular Cancer to be Conducted at MD Anderson Cancer Center Read More
Mukul Verma 1/4/23 Mukul Verma 1/4/23 Cancer Focus Fund Invests $5 Million to Support Human Trial of ISA's Immunotherapy to treat Uveal Melanoma Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in Rare Ocular Cancer to be Conducted at MD Anderson Cancer Center Read More
